Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer

Details for Australian Patent Application No. 2003244646 (hide)

Owner Aventis Pharma S.A.

Inventors Chakroun, Hichem

Agent Watermark

Pub. Number AU-B-2003244646

PCT Number PCT/EP03/07443

PCT Pub. Number WO2003/097164

Priority 60/380,850 17.05.02 US

Filing date 15 May 2003

Wipo publication date 2 December 2003

Acceptance publication date 7 August 2008

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

A61K 31/337 (2006.01) - having four-membered rings, e.g. taxol

A61K 31/351 (2006.01) - not condensed with another ring

A61K 31/66 (2006.01) - Phosphorus compounds

A61K 31/675 (2006.01) - having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

A61K 31/704 (2006.01)

A61P 15/00 (2006.01) Drugs for genital or sexual disorders

A61P 35/04 (2006.01) Antineoplastic agents

Event Publications

25 September 2003 Complete Application Filed

  Priority application(s): 60/380,850 17.05.02 US

29 January 2004 Application Open to Public Inspection

  Published as AU-B-2003244646

7 August 2008 Application Accepted

  Published as AU-B-2003244646

4 December 2008 Standard Patent Sealed

16 September 2010 Licence Registered

  Aventis Pharma S.A. ( sanofi-aventis Australia Pty Ltd )

3 February 2011 Licence Registered

  Aventis Pharma S.A. ( May & Baker Limited )

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003244647-Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation

2003244645-DIAGNOSTIC AND THERAPEUTIC USE OF A RAB FAMILY GTPBINDING PROTEIN FOR NEURODEGENERATIVE DISEASES